Aimmune’s peanut allergy med moves toward EU approval
CHMP grants Palforzia a positive opinion for the treatment of peanut allergic patients
Read More
Tag: Aimmune
Phase III results move Aimmune’s peanut allergy drug closer to EU market
Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance.
Read More
Aimmune’s peanut allergy drug hits PhIII targets
A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.
Read More
Promising data for Sanofi, Regeneron’s dupilumab
Sanofi and Regeneron have unveiled positive results from a mid-stage study exploring the potential of the biologic dupilumab in adults with eosinophilic esophagitis, and also signed a deal with Aimmune Therapeutics to test an experimental peanut allergy therapy.
Read More
First UK patient enrolled in peanut allergy trial
Children and adolescents in the UK with peanut allergy are among the first to enrol in a Europe-wide study investigating a new oral immunotherapy for the condition.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
